Search

Your search keyword '"Gerrit Stoter"' showing total 74 results

Search Constraints

Start Over You searched for: Author "Gerrit Stoter" Remove constraint Author: "Gerrit Stoter" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
74 results on '"Gerrit Stoter"'

Search Results

1. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-α: Course and relationship with psychiatric status

2. Interferon-alpha in oncology patients: Fewer psychiatric side effects than anticipated

3. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values

4. Molecular profiling of platinum resistant ovarian cancer

5. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer

6. IL-12: a promising adjuvant for cancer vaccination

7. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

8. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

9. Interleukin 12 induces activation of fibrinolysis and coagulation in humans

10. Intrapleural administration of tumour necrosis factor-alpha (TNFα) in patients with mesothelioma: cytokine patterns and acute-phase protein response

11. Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

12. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer

13. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer

14. Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects

15. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874

16. Paraneoplastic ophtalmoplegia and subacute motor axonal neuropaty associated with anti-GQ1b antibodies in a patient with malignant melanoma

17. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

18. Prognostic Factors in Metastatic Non-Seminomatous Germ Cell Tumours: An Interim Analysis of the EORTC GU-Group Experience

19. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study

20. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery

21. Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer

22. Carcinoma of unknown primary: Identification of a treatable subset?

23. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects

24. Analgesic adherence measurement in cancer patients: Comparison between electronic monitoring and diary

25. Late-onset retinoblastoma in a well-functioning fellow eye

26. EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

27. Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients

28. What is the role of dose-dense therapy?

29. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

30. Pegylated interferon-a2b, treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

31. Oral piritrexim, an effective treatment for metastatic urothelial cancer

32. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

33. Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

34. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFNα) in metastatic melanoma

35. Bleomycin and scuba diving: where is the harm?

36. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

37. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

38. Cisplatin - DNA adducts and protein-bound platinum in blood of testicular cancer patients

39. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

40. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer

41. Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats

42. Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis

43. Peripheral neurotoxicity induced by docetaxel

44. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia

45. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model

46. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

47. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitoury Tract Cancer Cooperative Group

48. Predictors of Residual Mass Histology Following Chemotherapy for Metastatic Nonseminomatous GCT: Univariate and Multivariate Meta-Analysis

49. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study

50. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer

Catalog

Books, media, physical & digital resources